TABLE 2

Most Commonly Reported AEs After 9vHPV to VAERS, 2014–2017

Report Characteristicsn (%)n (%)
All 9vHPV Reports
 Nonserious7058 Seriousa186
  Dizziness529 (7.5)  Headache63 (33.9)
  Syncope488 (6.9)  Dizziness50 (26.9)
  Headache355 (5.0)  Nausea48 (25.8)
  Injection site pain316 (4.5)  Fatigue42 (22.6)
  Injection site erythema314 (4.4)  Pyrexia35 (18.8)
Females
 Nonserious2142 Seriousa116
  Dizziness303 (14.1)  Headache41 (35.3)
  Syncope279 (13.0)  Dizziness37 (31.9)
  Headache211 (9.8)  Nausea31 (26.7)
  Injection site pain193 (9.0)  Fatigue29 (25.0)
  Nausea181 (8.4)  Asthenia27 (23.3)
Males
 Nonserious1501 Seriousa65
  Dizziness213 (14.2)  Headache21 (32.3)
  Syncope182 (12.1)  Nausea17 (26.2)
  Injection site erythema153 (10.2)  Vomiting16 (24.6)
  Headache141 (9.4)  Pyrexia14 (21.5)
  Pyrexia132 (8.8)  Fatigue13 (20.0)
  • Based on MedDRA Preferred Terms; a single report may be assigned more than 1 MedDRA Preferred Term (ie, not mutually exclusive).

  • a As defined in 21CFR600.80.21